Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
-$0.29 today
- Market cap
- $3.71B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
Volume 1.30M
Average 1.16M
XENE Total Current Liabilities
All obligations due within one year.
Xenon Pharmaceuticals Inc.NASDAQ: XENE
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities rises 18.2% from a year ago
Total current liabilities stood at $45.3M at the end of Q3 FY2026, up 18.2% from a year earlier and up 0.7% from the prior quarter. Over 3 fiscal years it compounded at +22.6% a year.
Context
- Total current liabilities amounted to 3.8% of total assets at the end of Q3 FY2026, down 2.5 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +18.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 41.79M USD
- Year-over-year change
- +17.4%
- 4-year CAGR
- +30.7%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.79M | +17.4% |
| FY2024 | 2024-12-31 | 35.59M | +30.5% |
| FY2023 | 2023-12-31 | 27.27M | +20.1% |
| FY2022 | 2022-12-31 | 22.7M | +58.5% |
| FY2021 | 2021-12-31 | 14.32M | — |
Total Current Liabilities vs competitors
How XENE compares with its peers on the latest reported figures
- XENE's Sep 2026 total current liabilities of $45.3M is the 8th highest of the 11 companies compared; the peer median is $211.15M.
- Its year-over-year change of +18.2% is the 5th highest of 11, against a peer median of +8.7%.
- Total current liabilities amounts to 3.8% of total assets for XENE, versus a peer median of 18.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $2.53B | +11.4% | +33.9% | 21.1% | |
| Sep 2026 | $984.6M | +54.3% | +11.4% | 17.5% | |
| Jun 2026 | $460.45M | +34.6% | +57.7% | 60.5% | |
| Jun 2026 | $347.38M | +21.3% | -21.1% | 24.3% | |
| Sep 2026 | $332.22M | -6.8% | +30.2% | 18.5% | |
| Jun 2026 | $90.08M | -1.1% | -35.3% | 7.8% | |
| Sep 2026 | $52.5M | -0.7% | +20.3% | 4.0% | |
| Sep 2026 | $45.3M | +18.2% | +22.6% | 3.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $30.12M | +6.1% | +11.0% | 19.6% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $17.9M | +90.7% | +125.4% | 3.6% |
| Dec 2025 | $6.37M | -51.5% | -4.3% | 4.8% | |
| Peer median (excluding XENE) | $211.15M | +8.7% | +15.8% | 18.0% | |
Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 175.69M | 57.24M | 148.64M | 142.71M | 199.16M |
| Short-term Investments | 376.09M | 534.85M | 489.44M | 484.19M | 349.72M |
| Net Receivables | 2.77M | 986K | 874K | 1.47M | 1.37M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 7.23M | 6.01M | 6.89M | 10.39M |
| Total Current Assets | 559.02M | 600.3M | 644.96M | 635.26M | 560.65M |
| Property, Plant & Equipment (Net) | 12.52M | 16.91M | 18.85M | 18.22M | 15.35M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 128.68M | 292.79M | 127.5M | 37.15M |
| Tax Assets | 465K | 509K | 802K | 9.67M | 361.37M |
| Other Non-current Assets | 0 | 7.75M | 7.4M | 7.5M | 7.15M |
| Total Non-current Assets | 12.99M | 153.85M | 319.84M | 162.88M | 421.02M |
| Total Assets | 572.01M | 754.15M | 964.8M | 798.14M | 981.67M |
| Account Payables | 3.82M | 8.49M | 8.6M | 5.07M | 3.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1.53M |
| Tax Payables | 0 | 0 | 0 | 5.69M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.94M | 5.82M | 347K | 9.93M | 21.6M |
| Total Current Liabilities | 14.32M | 22.7M | 27.27M | 35.59M | 41.79M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 348.51M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 3.2M |
| Total Non-current Liabilities | 7.65M | 9.95M | 9.6M | 7.65M | 358.12M |
| Total Liabilities | 21.97M | 32.65M | 36.88M | 43.24M | 399.91M |
| Common Stock | 783.17M | 1.07B | 1.44B | 1.46B | 1.6B |
| Retained Earnings | (357.37M) | (482.75M) | (665.14M) | (899.47M) | (1.25B) |
| Accumulated OCI | (990K) | (3M) | (77K) | (1.61M) | 335K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 550.03M | 721.5M | 927.92M | 754.9M | 581.76M |
| Total Debt | 8.26M | 10.44M | 10.9M | 9.02M | 7.94M |
| Net Debt | (167.43M) | (46.81M) | (137.74M) | (133.7M) | (191.22M) |
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
Intrinsic Alpha fair value
Locked
Current Price
$37.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.